SAN Sanofi

Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee

Press Release: François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee

 

François-Xavier Roger appointed Chief Financial Officer, member of Sanofi Executive Committee

Paris, February 1, 2024. François-Xavier Roger will be appointed Chief Financial Officer and a member of Sanofi’s Executive Committee effective April 1, 2024. He will be based in Paris and will succeed Jean-Baptiste Chasseloup de Chatillon who will step down from his role to become Head of Apprentis d’Auteuil. Apprentis d’Auteuil is a foundation that supports adolescents who are struggling in life by providing education, training and integration programs, in France and internationally. Being active in charity work for many years, Jean-Baptise decided to devote the next stage of his career to giving back to society.

François-Xavier will join from Nestle, where he has been the CFO for more than 8 years, providing strong financial leadership and driving sustainable value creation. He is a seasoned executive who has lived and worked in Europe, the U.S, Asia, Africa and Latin America. Before Nestlé, François-Xavier  was the CFO of Takeda Pharmaceuticals, based in Japan, from 2013 to 2015. François-Xavier started his career in pharma, spending the first 14 years at Roussel, Hoechst and Aventis, in various countries. From 2000 to 2008, François-Xavier was the CFO for Danone Asia, after which he was Head of Finance, Treasury and Tax for the Danone Group. Between 2008 to 2013, he was CFO of Millicom, a NASDAQ listed, global mobile phone operator.

Paul Hudson

Chief Executive Officer, Sanofi

“As we enter the next phase of launch and growth, it’s a pleasure to welcome onboard François-Xavier Roger, a CFO with a proven track record in accelerated value creation. Since joining in 2018, Jean-Baptiste de Chatillon has been instrumental in progressing our Play to Win Strategy. Under his leadership, our finance organization has been modernized into a team that supports our mission and execution of our strategy on a daily basis. We are proud of Jean-Baptiste’s next step.”

Jean-Baptise Chasseloup de Chatillon

“Over these last 5 years, I have been privileged to witness the incredible transformation of Sanofi into a company with a strong long-term growth potential. My decision to head Apprentis d’Auteuil was also fuelled by my growing passion for the impact Sanofi has around the world. I thank Paul and all my colleagues at Sanofi for their trust over the years and will be applauding them as they continue to drive forward our strategy.”

François-Xavier Roger

“It is with great enthusiasm that I join Sanofi in this dynamic moment marked by significant transformation. I am excited by the opportunity to further improve patient outcomes and deliver increased shareholder value in the years to come.”

 

Picture of François-Xavier Roger is attached to this email.





 

About Sanofi

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY

Media Relations

Sandrine Guendoul |  25 | 

Nicolas Obrist |  55 | 

Victor Rouault |  40 | 

Investor Relations

Eva Schaefer-Jansen |  39 | 

Arnaud Delépine |  93 |

Corentine Driancourt |  21 |

Felix Lauscher | + 1 908 612 7239 |

Tarik Elgoutni| 7 |

Nathalie Pham |  17 |

Attachments



EN
01/02/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

 PRESS RELEASE

Press Release: Sanofi commits an additional $625 million to Sanofi Ven...

Press Release: Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation Sanofi commits an additional $625 million to Sanofi Ventures to accelerate investment in biotech and digital health innovation The fund will remain focused on Sanofi's key areas of immunology, rare diseases, neurology, and vaccines, backing earlier-stage innovation and emerging opportunities that support the company’s long-term strategySanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering hea...

 PRESS RELEASE

Communiqué de presse : Sanofi engage 625 millions de dollars supplémen...

Communiqué de presse : Sanofi engage 625 millions de dollars supplémentaires dans Sanofi Ventures, afin d’accélérer ses investissements dans les biotechnologies et l’innovation en matière de santé numérique Sanofi engage 625 millions de dollars supplémentaires dans Sanofi Ventures, afin d’accélérer ses investissements dans les biotechnologies et l’innovation en matière de santé numérique Le fonds restera axé sur les domaines clés de Sanofi que sont l’immunologie, les maladies rares, la neurologie et les vaccins, en appuyant l’innovation en amont et les opportunités émergentes qui soutien...

 PRESS RELEASE

Press release: Availability of the Q3 2025 Aide mémoire

Press release: Availability of the Q3 2025 Aide mémoire   Availability of the Q3 2025 Aide mémoire Paris, France – September 24, 2025. Sanofi announced today that its Q3 2025 Aide mémoire is available on the "Investors" page of the company's website: As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items, as well as the foreign currency impact and share count. Sanofi's second quarter 2025 results will be published on October 24, 2025.    About ...

 PRESS RELEASE

Communiqué de presse : Mise en ligne du document "Q3 2025 Aide mémoire...

Communiqué de presse : Mise en ligne du document "Q3 2025 Aide mémoire" Mise en ligne du document «Q3 2025 Aide mémoire » Paris, France, le 24 septembre 2025. Sanofi annonce la mise en ligne sur l'espace Investisseurs du site internet de la société, d'un document intitulé « Q3 2025 Aide mémoire ». Comme chaque trimestre, ce document vise à assister la communauté financière dans la modélisation des résultats trimestriels de la société. Ce document contient un rappel de divers éléments non récurrents, l’effet des variations monétaires et le nombre d’actions. Les résultats du premier trime...

 PRESS RELEASE

Press Release: Sanofi’s SAR446268 earns US fast track designation for ...

Press Release: Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Sanofi’s SAR446268 earns US fast track designation for the treatment of non-congenital myotonic dystrophy type 1 Designation earned for one-time AAV gene therapy SAR446268, designed to silence DMPK expressionMyotonic dystrophy type 1 (DM1) is a rare, genetic disorder that causes progressive muscle weakness and wasting, with no currently approved medicines Paris, September 23, 2025. The US Food and Drug Administration (FDA) has granted fast track designation t...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch